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Abstract
The coauthors have been working together for ten years on serotonin, dopa-
mine, and histamine and their connection to neuropsychiatric illnesses. Hashemi
has pioneered many new experimental techniques for measuring serotonin and
histamine in real time in the extracellular space in the brain. Best, Reed, and Nijhout
have been making mathematical models of brain metabolism to help them interpret
Hashemi’s data. Hashemi demonstrated that brain histamine inhibits serotonin
release, giving a direct mechanism by which inflammation can cause a decrease in
brain serotonin and therefore depression. Many new biological phenomena have
come out of their joint research including 1) there are two different reuptake
mechanisms for serotonin; 2) the effect of the serotonin autoreceptors is not
instantaneous and is long-lasting even when the extracellular concentrations have
returned to normal; 3) that mathematical models of serotonin metabolism and
histamine metabolism can explain Hashemi’s experimental data; 4) that variation in
serotonin autoreceptors may be one of the causes of serotonin-linked mood disor-
ders. Here we review our work in recent years for biological audiences, medical
audiences, and researchers who work on mathematical modeling of biological
problems. We discuss the experimental techniques, the creation and investigation
of mathematical models, and the consequences for neuropsychiatric diseases.
Keywords: serotonin, histamine, depression, mathematical model
1. Introduction
It is worthwhile to begin by reminding ourselves that the question of depression
and the brain is so difficult because the brain consists of many different systems
that interact with each other. First is the electrophysiology of the brain including
the biophysics of individual neurons and the behavior of neural networks. Second is
the biochemistry of the brain, not just cell biochemistry and the structure and
function of receptors, but also the fact that many brain neurons do not do one-to-
one signaling with other neurons. These neurons, like the serotonin (5-HT) neurons
of the dorsal raphe nucleus (DRN) have dense projections to other brain regions in
which their axons have myriad varicosities that release the transmitter when the
neuron fires, thus changing the concentration of the transmitter in the extracellular
space of the projection region. In a sense, these neurons project changes in
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biochemistry over long distances in the brain. Example are the 5-HT projections
from the DRN to the striatum and the dopamine projection from the substantia
nigra to the striatum. Third is the genomics of the brain, not just the genotypes of
individuals but also how gene expression levels vary depending on electrophysiol-
ogy, biochemistry, and the other systems below. Fourth is the endocrine system.
The brain is an endocrine organ itself but is also influenced by other endocrine
organs such as the ovaries and the adrenal glands. Fifth, the brain is affected by the
current status of the immune system that affects the release of histamine frommast
cells. Sixth, the brain creates behavior but behavior affects the endocrine and
biochemical systems. And, these six systems operate on a wide range of spatial and
temporal scales.
There are four additional difficulties. The brain is not fixed like a machine, but is
dynamically changing on short and long time scales based on its challenges and
history of challenges. Secondly, direct in vivo experimentation on humans is
unethical, so one is left with remote sensing (imaging, drug responses, etc.) and
extrapolation from animal experiments often performed on tissue slices. Third,
there is an exceptional amount of individual variation. For example, it is known that
gene expression levels vary by about 25% from person to person [1–3] and of course
vary in time; so what does it mean to speak of “the brain?” Finally, not surprisingly,
a myriad of homeostatic mechanisms (such as 5-HT1B autoreceptors on 5-HT vari-
cosities) have evolved so that the brain can keep functioning “normally”, despite
changing inputs, gene polymorphisms, and enormous biological variation. These
mechanisms, whether gene regulatory networks or biochemical regulatory motifs,
operate over limited scales and are almost always nonlinear, and this makes
guessing the likely results of interventions very difficult.
In this situation where the system is complex and experimentation is difficult,
mathematical modeling can provide a useful tool. A model gives voice to our
assumptions about how something works. Every biological experiment is designed
within the context of a conceptual model and its results cause us to confirm, reject,
or alter that model. Conceptual models are always incomplete because biological
systems are very complex and incompletely understood. Moreover, and as a purely
practical matter, experiments tend to be guided by small conceptual models of only
a very small part of a system, with the assumption (or hope) that the remaining
details and context do not matter or can be adequately controlled. Mathematical
models are formal statements of conceptual models. Like conceptual models, they
are typically incomplete and tend to simplify some details of the system. But what
they do have, which experimental systems do not, is that they are completely
explicit about what is in the model, and what is not. Having a completely defined
system has the virtue of allowing one to test whether the assumptions and structure
of the model are sufficient to explain the observed results. The purpose of mathe-
matical models is not just to match extant experimental or clinical data, but to
provide an in silico platform for experimentation and investigation of system
behavior. Such experiments are quick and inexpensive and so are particularly useful
for testing hypotheses. Of course, to be useful, mathematical models should be
based as much as possible on the underlying physiology.
Janet Best is a mathematician at Ohio State, Michael Reed is a mathematician at
Duke University and H. Frederik Nijhout is a biologist at Duke. They have been
working together on brain metabolism since 2008. They began by creating a large
mathematical model of dopamine (DA) synthesis, storage in vesicles, catabolism,
release, reuptake and control in synapses and varicosities [4] and a similar model
for serotonin [5]. They used these models (and simpler ones) to study many phe-
nomena, including passive and active stabilization of DA in the striatum [6], the
role of 5-HT in the striatum [7], and the interaction of DA and 5-HT in the striatum
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in levodopa therapy for Parkinson’s disease [8, 9]. Their papers on brain metabolism
are available on the website sites.duke.edu/metabolism.
Parastoo Hashemi is an electrochemist and biomedical engineer at Imperial
College London and the University of South Carolina. She was the first experimen-
talist to be able to measure the time course of 5-HT concentration and histamine
concentration in the extracellular space of the brain in vivo [10]. In 2013, she
contacted Best, Reed, and Nijhout and asked for help interpreting the results of her
experiments, and the four us have been actively collaborating since then. All of our
joint papers are available on the above website. Our collaboration always begins by
active discussion of new experimental results that often change our previous
understanding and therefore require changing previous models. The new models
then often suggest new experiments to test new hypotheses that come from model
experimentation. In this review, there will be many examples of this back and forth
between experiment and modeling that we have found to be very productive. Anna
Marie Buchanan is a graduate student in the Department of Chemistry and Bio-
chemistry at the University of South Carolina.
In Section 2 we discuss the importance of homeostatic mechanisms in the brain.
In Section 3 we discuss our first modeling paper with the Hashemi Lab [11]. That
paper changed our understanding of 5-HT1b autoreceptors and showed that the way
we modeled autoreceptors in 2010 [5] was wrong. Section 4 describes our 2017
paper [12] creating a mathematical model for histamine dynamics in the brain and
Section 5 discusses our 2020 paper [13] revising and expanding our original 5-HT
model. In Section 6 we briefly describe the techniques for measuring 5-HT and
histamine in the extracellular space and in Section 7 we describe our ideas and
speculations about depression. Lastly, in Section 8 we discuss future work.
2. Homeostatic mechanisms
The extracellular space occupies a significant portion of brain volume and is
extremely important. Not only is it the medium by which nutrients in the plasma
are delivered to brain cells but it is all one important medium for communication
between cells. Thus, it is not surprising that a variety of mechanisms have evolved
to control the extracellular concentrations of neurotransmitters in different brain
regions within fairly narrow limits. For example, DA is synthesized from tyrosine
by tyrosine hydroxylase (TH) and TH shows substrate inhibition as does trypto-
phan hydroxylase (TPH) that synthesizes 5-HT from tryptophan. And, the concen-
tration of DA in the extracellular space inhibits both synthesis and release of DA via
the DA autoreceptors, a kind of end product inhibition. Similar mechanisms exist
for 5-HT via the 5-HT autoreceptors. We will discuss the 5-HT autoreceptors in
detail later. Our purpose here is to show what this homeostasis looks like and what
the consequences are for DA.
The main determinants of the DA concentration in the extracellular space are
rate of release from synapses and varicosities and rate of reuptake by the dopamine
transporters (DATs). Release is dependent on the rate of synthesis via TH. Figure 1
shows the concentration of DA in the extracellular space as a function of TH activity
and DAT activity, computed by our 2009 mathematical model [4]. The normal
steady state of the model is indicated by the large white dot that corresponds to
100% TH and DAT activity. The genes for TH and DAT have many common poly-
morphisms in the human population. The steady state extracellular DA concentra-
tion for combinations of these polymorphisms are shown by the small white circles
on the surface. It’s quite amazing, but all these points are on the homeostatic
(approximately flat) part of the surface. Even though these polymorphisms are
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functional, that is they have big effects on the activities of TH and DAT, they do not
affect the extracellular concentration of DA very much. This homeostasis is created
by the above two mechanisms, substrate inhibition and the autoreceptors. From an
evolutionary point of view maybe the fact that the steady states for the polymor-
phisms are on the flat part of the surface is not surprising. If a polymorphism
pushed the steady up the blue cliff in the back (as in cocaine addiction) or off the
orange cliff in the right front (as in Parkinson’s disease) then that polymorphism
would not likely be common in the human population. It’s interesting to consider
the row of polymorphism steady states nearest the orange cliff. They are on the
homeostatic part of the surface, but barely. One could think of them as
“predisposed” to low DA diseases. In fact, individuals with this low TH activity
polymorphism often show muscle dystonia and other symptoms of low DA [14].
The surface in Figure 1was computed assuming variation in TH and DAT, but there
are many other variables in the system, for example monoamine oxidase (MAO),
and variations in those variables could change the locations of the white dots.
The point is that the existence of homeostatic mechanisms make linear argu-
ments that assume that a large change in one variable automatically results in large
changes in downstream variables both simplistic and often wrong. Therefore, it is
important to investigate and understand homeostatic mechanisms in the brain and
their consequences.
3. Revised understanding of serotonin dynamics
Efforts to understand the serotonergic system and in particular the clearance
dynamics of serotonin date back decades, but results were limited by experimental
technology. Only recently has the Hashemi Lab been able to measure serotonin
concentrations in the extracellular space in vivo. With early fast scan cyclic
voltammetry (FSCV, see Section 6) experiments, the Wightman lab was able to
measure release and clearance of serotonin in electrically stimulated rat brain slices
Figure 1.
Dependence of extracellular DA on TH and DAT activity. The large white dot shows the extracellular DA
concentration when TH and DAT have normal activity, where, for each variable, normal is scaled to 1. The
normal steady state is in the middle of a large relatively flat plateau, extracellular DA does not change much as
TH and DAT activity vary. The small white dots show the steady states for different combinations of TH and
DAT polymorphisms common in the human population. Though these polymorphisms are functional, in that
they have large effects on activity, they do not affect extracellular DA very much. This homeostatic effect is
created by the dopamine autoreceptors.
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[15]. The data were fit to a simple model for release and Michaelis–Menten reuptake
of serotonin. Further experimental innovation enabled Hashemi to evoke the release
of serotonin upon stimulation of the medial forebrain bundle (MFB), and measure
the release and clearance in vivo in rat substantia nigra pars reticulata (SNr). In an
early paper, average release and clearance data for five mice was fit with the
Wightman model for release and reuptake [10].
Subsequent efforts in mice to elucidate the serotonergic system with its response
to antidepressants and autoreceptor antagonists revealed that serotonin responses
are actually heterogeneous, and that averaging the responses obscures potentially
important phenomena [11]. Furthermore, some of the data could not be fit well
with the Wightman model, as the Km value appeared to change during the thirty
second experiment. These data were the impetus for Hashemi to contact modelers
Best, Reed, and Nijhout to suggest collaboration.
The mouse SNr data showed three distinct serotonin responses to a standard
MFB stimulation, primarily differentiated by the clearance slopes, motivating our
adoption of the terminology fast, slow, and hybrid. All three responses have a rapid
rise. Fast responses are characterized by a rapid return to baseline, while slow
responses show a more gradual, linear, return to baseline. Hybrid responses have
both fast and slow attributes, descending rapidly for a short time and then
switching to a slower decay. See Figure 2.
Our model, shown below, employs release and Michaelis–Menten clearance
kinetics similar to the Wightman model. However, our model additionally incorpo-
rates a second reuptake mechanism, a basal concentration of serotonin, and
autoreceptor effects. S tð Þ½  denotes the concentration of serotonin in the SNr extra-
cellular space. We assume that S tð Þ½  satisfies the differential equation:
Figure 2.
Fast, slow, and hybrid responses. The three panels on the left show fast (A), slow (B), and hybrid (C) responses
measured in the SNr after stimulation of the MFB [11]. The blue curves are experimental data and the red
curves come from a simple mathematical model in which the auto receptor effect was changed as a function of
time (green curves in the right panels). The data and the modeling provided the first in vivo evidence of two
distinct reuptake mechanisms for 5-HT and also showed that autoreceptor effects are long lasting and continue
after 5-HT concentrations have returned to baseline.
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dS tð Þ½ 
dt
¼ R tð Þ 1 A tð Þð Þ  α
V max 1 S tð Þ½ 
Km1 þ S tð Þ½ 
 β
V max 2 S tð Þ½ 
Km2 þ S tð Þ½ 
(1)
where R tð Þ is the rate of release and A tð Þ is the fraction of stimulated
autoreceptors. R tð Þ represents the neuronal firing in the DRN upon stimulation of
the MFB and subsequent release of serotonin in the SNr. Firing rises and decays
quickly (but not instantaneously) in response to the stimulation due to the non-
instantaneous excitation/relaxation of the MFB-DRN-SNr circuitry. The two
Michaelis–Menten reuptake mechanisms have different Vmax and Km values. V max 1
and Km1 correspond to slow responses, while V max 2 and Km2 correspond to fast
responses. The constants α and β are the weights of the two reuptake mechanisms.
For fast responses α ¼ 0 and β ¼ 1, for slow responses α ¼ 1 and β ¼ 0. For hybrid
responses, α is taken as 1 at all times, while we incorporate β in a graded,
concentration-dependent manner. When S tð Þ½  is >44 nM, β is 0.03 and then
decays linearly to 0 as S tð Þ½  decreases from 44 nM to 39 nM and β ¼ 0 when S tð Þ½  is
< 39 nM, meaning that the reuptake associated with β is low affinity and so loses
effectiveness at low concentrations. Thus hybrid responses have contributions from
both reuptake mechanisms.
Figure 2 shows the model curves (magenta) superimposed onto the three
experimental serotonin response types (black). We found that the following Vmax
and Km values fit well to the experimental data: V max 1 = 17.5 nM s1, Km1 ¼ 5 nM
and V max 2 =780 nM s1, and Km2 ¼ 170 nM, respectively. These values were fixed
for all simulations while the choices of α, β differed as indicated above. These Km
and Vmax values agree remarkably well with high affinity, low efficiency (Uptake 1)
and low affinity, high efficiency (Uptake 2) as had been suggested by Snyder and
colleagues [16]. Daws and colleagues verified pharmacologically that Uptake 1 is
likely to occur primarily via serotonin transporters (SERTs) on serotonergic neu-
rons and Uptake 2 includes other transporters on other cells including the dopamine
transporter, the norepinephrine transporter, and the organic cation transporter
[17, 18]. Our dataset, reviewed here, was the first endogenous, in vivo data to
support the concept of these two distinct uptake mechanisms for serotonin. We
remark that the Uptake 2 parameters that worked well for us are exactly the
parameters used by Shaskan and Wightman to match their experimental data. Note
that the Uptake 1 parts of the response curves are quite linear, which shows that the
SERTs are saturated.
The R tð Þ and A tð Þ functions for each response are shown in Figure 2. We assume
that in each case the baseline concentration of 5-HT in the extracellular space is
20 nM. For all three response types, we found that the model fit well with the
autoreceptor effect increasing linearly after 12 sec and continuing through the end
of the 30 sec experiment. To test our model’s suggestion of autoreceptor control
experimentally, we treated mice with methiothepin, a non-selective serotonin
receptor antagonist with highest affinity for the serotonin autoreceptors [19].
We were able to fit the data with the hybrid model, setting the autoreceptor
function A tð Þ to zero. In our previous model [5], the autoreceptor effect was an
instantaneous response to the current extracellular serotonin concentration.
Modeling this data revealed that the autoreceptor response differs from our earlier
model in two important ways: it is not instantaneous, and it lasts well beyond when
the extracellular serotonin concentration returns to baseline; see Figure 2. These
observations motivated us to improve our autoreceptor model, see Sections 4 and
5, although we would also learn that the autoreceptors were not solely responsible
for these effects in the data. Note that in Panels A and C the concentration is well
below baseline at t ¼ 30 and still decreasing. We will come back to this issue in
Section 5.
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4. A model for histamine with new autoreceptors
Histamine is a small molecule that plays an important role in the immune system
[20]. In the brain, histamine is stored in mast cells and other non-neuronal cells
(containing roughly half of brain histamine [21, 22]), but it also occurs as a neuro-
transmitter [23]. The neuronal cell bodies are in the tuberomammillary nucleus of the
hypothalamus and these neurons send projections throughout the CNS, in particular
to the cerebral cortex, amygdala, basal ganglia, hippocampus, thalamus, retina, and
spinal cord [20]. Histamine neurons make few synapses, but release histamine from
the cell bodies and from varicosities when the neurons fire. Thus the histamine neural
systemmodulates and controls the histamine concentration in projection regions [23].
Understanding the control of histamine in the extracellular space is important
because we have shown that the release of histamine inhibits 5-HT release in the
hypothalamus [24]. We stimulated the MFB and measured histamine and 5-HT
simultaneously in the extracellular space of the hypothalamus in vivo in mice; see
Figure 3. In Panel (a), the blue curve shows the average histamine curve in the
extracellular space for 5 animals. The curve peaks shortly after the 2 second
Figure 3.
Histamine inhibits 5-HT. Stimulation of the MFB releases histamine but not 5-HT in the hypothalamus. The
blue curve in (A) shows extracellular histamine as a function of time and the maroon curve in (B) shows the
corresponding inhibition of 5-HT release. 5-HT does not return to baseline even after histamine has returned to
baseline because of the long-lasting effect of the H3 histamine receptors on 5-HT varicosities. The green and
orange curves show the histamine and 5-HT responses in the presence of thioperamide, a potent H3 antagonist.
Error bars showing SEM (n = 5 SEM) are lighter versions of the respective colors. Horizontal bars at 0 μM
and 0 nM indicate the timing of the stimulus. Predictions of a simple mathematical model are shown by the dots.
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stimulation from t = 5 sec to t = 7 sec, and then descends to slightly below baseline
by t = 30 sec. Clearance of histamine from the extracellular space is likely due to its
recycling via transport back into the cytosol. While such a histamine transporter has
not been identified, our unpublished experimental data shows that it is hard to
deplete vesicular stores, strongly suggesting that extracellular histamine must be
reuptaken into the cytosol. As we will see, the descent below baseline is caused by
H3 receptors on the histamine varicosities that inhibit histamine release. Simulta-
neous average measurement of 5-HT in the extracellular space is shown by the
maroon curve in Panel (b). As the histamine curve peaks in Panel (a), the 5-HT
curve plunges in Panel (b). As the histamine recovers to baseline in Panel (a), the 5-
HT curve in Panel (b) rebounds partway towards baseline and then levels off below
baseline. It is known that there are histamine H3 receptors on 5-HT neurons that
inhibit 5-HT release [25, 26]. These curves show that the effect is long-lasting. In
order to test these ideas, we redid the experiments in the presence of thioperamide,
a potent H3 receptor antagonist [27]. Now the histamine curve (green) in Panel (a)
goes up higher and descends more slowly. The corresponding orange 5-HT curve in
Panel (b) descends even further and rebounds less. Its complicated behavior prob-
ably results from two competing influences: histamine concentration is higher but
thioperamide also partially blocks the H3 receptors on the 5-HT varicosity. The
white dots come from a simple mathematical model in which we adjusted the
strengths of H3 receptor effects on both of the varicosities by hand. The fact that we
could match these curves by doing that provided further confirmation that the
results of the experiments were due to H3 receptors. We note that the scales in
Panels (a) and (b) are very different, μM and nM.
These experiments and their interpretation provide a likely mechanism by
which the neuroinflammation that occurs in a variety of disorders could cause
depression. We therefore concluded that it was important to construct a full model
of the synthesis, vesicular storage, release and reuptake of histamine, and control in
the extracellular space by histamine autoreceptors [12]. Overall, this model is sim-
ilar to the model that we constructed for serotonin [5]. In the case of both neuro-
transmitters, autoreceptors on the surfaces of varicosities inhibit release when the
extracellular concentration is high and diminish the inhibition when the extracellu-
lar concentration is low; this is clearly a mechanism to stabilize the extracellular
concentration. In our original serotonin paper [5], we modeled this inhibition to be
instantaneous as a phenomenological response to the current concentration of neu-
rotransmitter in the extracellular space. However, as described in the previous
section, our FSCV data and modeling [11] showed that autoreceptor effects are
long-lasting and persist even when the concentration in the extracellular space has
returned to normal. This is almost certainly because the cellular machinery that
creates the inhibition and the decay of that machinery take time. Therefore, in our
histamine model we introduced a minimal mathematical model of signal transduc-
tion at the G-protein coupled autoreceptor consisting of a G-protein subunit and a
regulator of G-protein signaling (RGS) protein.
Figure 4 shows a schematic of the model. The pink boxes indicate substrates
that are variables in the model and the gray ovals contain the acronyms of enzymes
and transporters. Histidine in the blood (bHT) is transported into the varicosity by
the histidine transporter (HTL) where it becomes cytosolic histidine (cHT) or goes
into the histidine pool (HTpool). Most of the histidine that enters the cell is used for
other processes than making histamine and that is what the HTpool represents. cHT
is converted to cytosolic histamine, cHA, by the enzyme histidine decarboxylase,
HTDC. Some cHA is catabolized by the enzyme histamine methyltransferase,
HNMT, some is transported into the vesicles by the monoamine transporter, MAT,
and becomes vesicular histamine, vHA, and some leaks out of the cytosol into the
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extracellular space (indicated by the dashed line). vHA is released into the extracel-
lular space, at a rate proportional to neuronal firing, where it becomes extracellular
histamine, eHA. In the extracellular space, eHA has several fates. It can be
transported back into the cytosol by a putative histamine transporter, HAT. It can
diffuse away (removal). It can be transported into glial cells where it becomes glial
histamine, gHA, which then leaks out or is catabolized by HNMT. Finally, eHA can
bind to the H3 histamine autoreceptor. The concentration of histamine bound to the
autoreceptor, bHA, stimulates the conversion of the G-protein subunit, G, to its
activated state, G ∗ . And, G ∗ stimulates the conversion of the RGS protein,T, to its
activated state, T ∗ , in which it facilitates the conversion of G ∗ back to G. It is the
activated G-protein subunit, G ∗ , that inhibits release and synthesis of histamine.
We remark that we only track T ∗ and G ∗ since total G-protein, GþG ∗ , is assumed
constant, as is T þ T ∗ .
The H3 histamine receptor (the autoreceptor in this case) is in the rhodopsin
family of G-protein coupled receptors [28]. The binding of an extracellular hista-
mine molecule to the autoreceptor causes the release of a G-protein subunit that
stimulates a signaling cascade that results in inhibition of release and synthesis.
Most G-protein signals are limited by RGS molecules that stimulate the G-protein
subunit to rebind [29]. In our minimal model, G represents Gα  GDP (the inactive
G-protein subunit) and G ∗ represents Gα  GTP (the signaling G-protein unit).
Similarly, T represents the inactive RGS protein and T ∗ represents the active RGS
protein.
In our model, b0 is the total concentration of autoreceptors and bHA is the
concentration of receptors bound to eHA. Normally, G and G ∗ are in equilibrium
and their sum is constant (g0). The concentration of bound autoreceptors (bHA)
Figure 4.
Schematic of the mathematical model for histamine. bHT and cHT represent blood histidine and cytosolic
histidine, respectively. cHA, vHA, eHT, H3  bHA, and gHA represent cytosolic histamine, vesicular
histamine, extracellular histamine, histamine bound to autoreceptors, and glial histamine, respectively. G ∗ and
G represent activated and inactivated autoreceptor G-proteins and T ∗ and T represent activated and
inactivated regulators of G-proteins. Names of enzymes and transporters are as follows: HTL, the histidine
transporter; HTDC, histidine decarboxylase; HNMT, histamine methyltransferase; HAT, the putative
histamine transporter; H3, histamine autoreceptor; HTpool, the histidine pool.
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drives the equilibrium towards G ∗ . Similarly, T and T ∗ are at equilibrium and their
sum is a constant (t0). G
∗ drives the equilibrium towards T ∗ . T ∗ , in turn, drives
the equilibrium between G and G ∗ back towards G. The concentration of G ∗ affects
the release of histamine from the vesicular compartment through the function
inhib G ∗ð Þ ¼ 2:4015 2:45ð ÞG ∗ , and this same function appears in the formula for
the velocity of the synthesis reaction (HTDC). Since G ∗ ¼ :6945 at equilibrium,
tonically the inhibition is 0.7. As G ∗ tð Þ rises the inhibition gets stronger and if G ∗ tð Þ
decreases the inhibition becomes weaker.
The shape of the model prediction for eHA reflects the dynamics of bHA, G ∗ ,
and T ∗ . These curves are depicted in Figure 5 along with the graph of eHA. As one
can see, eHA goes up first, followed by an increase in bHA, the concentration of
bound autoreceptors. This causes a rise in G ∗ that in turn causes a rise in T ∗ that
makes G ∗ start to decline. The inhibition of release given by the function inhib G ∗ð Þ
depends on G ∗ as described above. This is the long-lasting autoreceptor effect. The
dynamics of G ∗ and T ∗ plays out over the full 30 seconds and drives the eHA
concentration below baseline. This autoreceptor model will be used for H3 receptors
on serotonin varicosities in Section 5. Full details of this histamine model can be
found in [12].
5. The new serotonin model
In 2010, three of the authors (JB, HFN, MCR) created a mathematical model of
serotonin synthesis in varicosities, storage in vesicles, release into the extracellular
space, reuptake by serotonin transporters (SERTs), and control by serotonin
Figure 5.
Autoreceptor variable dynamics in the model after stimulation. Release of histamine causes extracellular
histamine to rise and then descend as histamine is transported back into the cytosol and into glial cells (green
curve in A). The rise in eHA causes the concentration of bound autoreceptors to rise (red curve in Panel A). The
rise in bHA causes activation of G-proteins that inhibit release and synthesis of histamine (blue curve in Panel
B). The rise in G ∗ activates the G-protein regulator, T ∗ (pink curve in Panel B) and T ∗ starts to deactivate
G ∗ . It is this dynamics that causes the H3 receptor effect to be long-lasting.
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autoreceptors [5]. In subsequent years, they used the model to study and evaluate
various hypotheses about serotonergic function including connections with dopa-
minergic signaling [8, 30], bursts in the DRN [31], the effects of serotonin on
levodopa therapy [9], and serotonin dynamics in the basal ganglia [7]. In 2013, they
began the collaboration with Parastoo Hashemi, which led to new insights into
serotonergic function [11, 24, 32]. As discussed in Section 3, the experimental
results in [11] and later papers revealed that various aspects of the 2010 model were
naive and too simplistic. So, in 2020, the authors and collaborators expanded and
revised the original model to take account of the new findings that we had learned
[13]. Here we will briefly discuss the changes and some of the new results. A
schematic diagram of the new model is in Figure 6.
In the experiments in the Hashemi Lab, the MFB is stimulated for 2 seconds and
the antidromic spikes excite the DRN. The DRN sends bursts of action potentials to
projection regions such as the SNr, the pre-frontal cortex (PFC), and the hippo-
campus. Serotonin rises rapidly in the extracellular space in the projection regions
and then typically plunges substantially below basal levels within 30 seconds
[11, 13, 33–35]. This almost certainly is because inhibition of release by the
autoreceptors continues well after the serotonin concentration in the extracellular
space has returned to basal levels. In our 2010 model, extracellular serotonin
instantaneously affected release, and the Hashemi experiments showed that this is
wrong. Therefore, in our new model [13] we include a biochemical model of the
Figure 6.
Schematic diagram of the model. The rectangular boxes indicate substrates and blue ellipses contain the
acronyms of enzymes or transporters. The names of the most important substrates are: Btrp, blood tryptophan;
trp, cytosolic tryptophan; htp, 5-hydroxytryptamine; cht, cytosolic serotonin; vht, vesicular serotonin; eht,
extracellular serotonin; hia, 5-hydroxyindoleacetic acid; ght, glial serotonin; eha, extracellular histamine.
Names of enzymes and transporters are as follows: Trpin, neutral amino acid transporter; DRR,
dihydrobiopterin reductase; TPH, tryptophan hydroxylase; AADC, aromatic amino acid decarboxylase; MAT,
vesicular monoamine transporter; SERT, 5-HT reuptake transporter; auto, 5-HT1B autoreceptors; MAO
monoamine oxidase; ALDH, aldehyde dehydrogenase; NET, norepinephrine transporter; DAT, dopamine
transporter; OCT, organic cation transporter. Removal means uptake by capillaries or diffusion out of the
system.
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cellular dynamics caused by serotonin binding to the autoreceptor, including acti-
vated receptor G-proteins and activated regulators of G-proteins. This autoreceptor
model is similar to the histamine autoreceptor model discussed in Section 4. In
addition, we showed in [24, 36] that histamine in the extracellular space inhibits the
release of serotonin from serotonin varicosities. Therefore, in the new model, we
also include a biochemical model of a histamine H3 receptor on the serotonin
varicosity that changes the dynamics of serotonin release. Both of these biochemical
models for receptors are indicated schematically in Figure 6. As described in Sec-
tion 3, in [11] we also showed that there are two different serotonin uptake mech-
anisms, SERTs that pump serotonin back into the varicosities and another uptake,
which we call Uptake 2, that pumps serotonin into glial cells [16, 18, 37]. The
kinetics of the two uptakes are quite different and both are included in our new
model. We also include the effects of serotonin binding protein (SBP) that binds
serotonin tightly in vesicles but releases it quickly when the vesicles open to the
extracellular space. We also include leakage of 5-HT from the cytosol of neurons
and glial cells into the extracellular space (dashed lines). All details of these changes
and the full mathematical model can be found in [13]. We discuss below our new
model for release from the vesicles. We also made a systems population model from
our deterministic model and will show below how we used it to investigate certain
aspects of the serotonin system.
In our model there is a constant basal rate of serotonin release at steady state.
The question is how should we model release during the Hashemi Lab experiments
where the MFB is stimulated for two seconds? In our previous work using the 2010
model we simply increased the firing rate for the two seconds of stimulation and
then dropped it back to the basal rate. This issue is complicated by the existence of
serotonin binding protein (SBP) that is attached to the inner wall of vesicles and





If we start with one unit (nM) of SBP-serotonin being released into the extra-
cellular space at time zero, then SBP tð Þ ¼ ebt and serotonin tð Þ ¼ 1 ebt. The rate of
release of serotonin is the derivative, bebt: However, we are stimulating for two
seconds, so SBP-serotonin complexes are continuously released into the extracellu-
lar space between t ¼ 0 and t ¼ 2 seconds. Assume that the rate of release is 1 nM/
sec, so in two seconds, 2 nM of the complex are released. What is the rate of
appearance, R tð Þ, of free serotonin for t≤ 2 and t> 2?




b tsð Þds for t≤ 2, (3)
and




b tsð Þds for t> 2: (4)
Here χ s,2½  is the function that is 1 on the interval s, 2½  and zero otherwise.
A straightforward calculation shows that:
R tð Þ ¼
1 ebt if t≤ 2,
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Thus, for a two second stimulation, the rate of release will be proportional to
fire tð Þ ¼ basal rate þ r  R tð Þwhere r is the strength of the stimulation. Unfortu-
nately, the dissociation constant b (inverse seconds) is not known, but we think it is in
the range 0:5≤ b≤ 2 from our simulations of the Hashemi data, so we take b ¼ 1 as our
baseline case. The release of serotonin into the extracellular space will also be propor-
tional to vht and it will also depend on the inhibition from the serotonin autoreceptors









 basal rateþ r  R tð Þð Þ  vht: (6)
One of the first things that we did with our new model was to return to the 2014
data [11] that we discussed in Section 3 to see if our new serotonin model could
easily match the average curves of fast, slow, and hybrid in the SNr, with relatively
few, understandable changes of parameters. The experimental curves for fast, slow,
and hybrid (Figure 2) do not look like typical response curves measured in the
Hashemi Lab. For example, Figure 7 shows an average of 17 male responses in the
CA2 region of the hippocampus. Typical response curves peak, descend towards
baseline, drop below baseline, and then curve back towards baseline, whereas the
experimental curves in Figure 2 keep descending. In thinking about this, we
remembered that when the MFB is stimulated not only is 5-HT released in the SNr
but histamine is also released. So we were in a good position to see if our new
serotonin model, with its H3 receptor, would allow us to match the 2014 SNr data.
Unfortunately, we do not have the time course of histamine in the SNr in those
experiments, because in 2014 the Hashemi Lab had not yet optimized the tech-
niques to simultaneously measure 5-HT and histamine in vivo [24, 36]. So we will
take our histamine time course in the extracellular space, eha, from the control and
model curves in Figure 5 of [12]. Note how complicated the dynamics of eht are.
When one stimulates the MFB, serotonin is released into the extracellular space





However, histamine also increases in the extracellular space stimulating dynamical




ha. Both of the activated G-proteins,
G ∗ht and G
∗










Typical 5-HT response curves. The red dots show the average response of 23 male mice in the CA2 after
stimulation of the MFB. The blue curve shows the average response predicted by the new 5-HT model. 5-HT
rises rapidly and then descends rapidly as it is taken up by SERTs and Uptake 2. The concentration descend
below baseline and then curve back towards baseline. This is the long-lasting autoreceptor effect. The average
curve is simple and easy to interpret, but the individual curves show great variation; see Figure 8.
13
Mathematical Models of Serotonin, Histamine, and Depression
DOI: http://dx.doi.org/10.5772/intechopen.96990
Furthermore, Uptake 2 is rapid but it probably also depends on the distance of glial
cells from the electrodes in the three cases. Nevertheless, it was surprisingly easy to
give adjustments for a small number of parameters that distinguish between fast,
slow, and hybrid responses (see Figure 5 and Table 5 in [13]). The parameters that
we had to change were the Vmax of Uptake 2, the cutoff for Uptake 2, the strength of
the inhibition by the 5-HT1B and H3 receptors, and the strength of firing during
stimulation rð Þ. It is completely reasonable that these parameters would be different
for different electrode placements and different densities of receptors on the
neuron. No other parameters were changed.
The model we have been discussing is a differential equations model (ODE);
there is one differential equation for each of the pink boxed variables in Figure 6.
All individuals, whether mouse or human, are different, and the variation is
important for understanding experimental results and for precision medicine. We
investigate this biological variation by creating a systems population model of the
deterministic model given above. It is known that the expression levels of most
enzymes can vary by about 25% or more between individuals [1–3]. Therefore, to
create a systems population model, we choose new Vmax values for each (or a
subset) of the enzymes and transporters in Figure 6 by selecting independently
from a uniform distribution between 75% and 125% of the normal value. We then
run the model to steady state and record all the concentrations and velocities. That
is one virtual person (or mouse). If we do this 1000 times, we obtain a database of
virtual individuals that we can analyze using the usual statistical tools. The differ-
ence is that all of these individuals have the same set of differential equations; only
the coefficients are different. So we can experiment with the model to find the
mechanistic reasons for particular statistical phenomena. We will give several
examples that show why this approach is useful.
The steady state of eht in the ODEmodel is 60 nM; this should be thought of as the
steady state for an average mouse (or an “average” person).We allowed theVmax
values of TRPin, TPH, AADC,MAT,MAO, Uptake 2, and SERT to vary by 25% above
and below their normal values independently. In addition, we allowed fire tð Þ to vary
25% above and below its normal value and we vary the strength of the 5-HT1B
autoreceptors similarly. Distributions of eht in various cases are shown in Figure 9. The
green bars in Panel B show the distribution of eht values with normal tryptophan in the
blood. The green bars are similar to distributions measured in the Hashemi Lab. The
whole distributionmoves left (the yellow bars in Panel B) if blood tryptophan is
lowered from its normal values of 96μM to 50μM. In Panel A, we showwhat the
distribution of ehtwould look likewith no autoreceptors (orange bars) or autoreceptors
that are twice strong. Thus, the systems population model allows one to see the effects
of changes on a whole population, not just on an individual. Further, if the underlying
ODEmodel is a good representation of the real physiology, then the variation in the
populationmodel should correspond to what is seen in the Lab. This gives another way
of testing the validity of the underlying ODEmodel.
In [13] we used the ODE model to fit the average response curves for male and
female mice in the hippocampus. Here we want to discuss the variation in the
response curves. Panel A of Figure 8 shows the responses of the 17 male mice. The
experimental responses are measured and graphed for each mouse relative to the
baseline level of eht that is represented in Panel A by eht ¼ 0: One can see how large
the variation is. The curves peak at different times and at different heights. Most,
but not all, of the curves descend below baseline and their shapes are quite differ-
ent; some continue descending while others reach a minimum and then rebound
towards zero. The thick red curve is the mean and the thick black curve is the
standard deviation, which is substantial even between 15 seconds and 30 seconds
although the stimulation was only between t = 5 sec and t = 7 sec.
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We investigated what variation in the main parameters of the model would be
necessary to obtain the variation seen in the experiments. To do this we created a
virtual population of 1000 individuals. The following parameters were varied uni-
formly from 40% below to 40% above their normal values: the Vmax values for
VAADC, VCATAB, VMAT, VSERT, VTPH, VU2; the slope of inhib and inhibsyn; eha, the
concentration of histamine in the extracellular space, and β that controls the speed
of the autoreceptors. In addition, we varied the parameter r in fire tð Þ by 25% and the
time of the peak by 20%. Panel B of Figure 8 shows a random sample of 17 of the
1000 model male curves. The thick red curve is the mean of the 1000 model curves
and the thick black curve is the standard deviation. The mean curve matches the
experimental mean curve very well. The model standard deviation curve is very
close to the experimental standard deviation except that at long times (20 second to
30 seconds) it descends slightly while the experimental standard deviation remains
constant. Overall, one can see visually that the 17 model curves and the 17 experi-
mental curves look similar as groups of curves. For each of the 1000 individuals, we
record their steady state values as well as the values of all of their parameters so we
can use multi-linear regression to find which parameters contributed most to the
variation in the response curves. At t ¼ 7 sec (roughly the time of the peak), the
three variables that contributed most, in order, were the strength of fire(t), the
timing of the peak in fire(t), and the Vmax of the SERTs. At t ¼ 15 sec (when most of
Figure 9.
Distributions of extracellular serotonin. Panel A shows the distribution of eht if there is no autoreceptor effect
(pink bars) or if the autoreceptor effect is twice as strong as normal (blue bars). The green bars in panel B show
the distribution of eht if the autoreceptor effect is “normal”. The green bars are similar to distributions measured
in the Hashemi lab. The yellow bars in panel B show the distribution of eht if blood tryptophan is lowered from
its normal value of 96μM to 50μM. the distribution of eht moves substantially lower.
Figure 8.
Individual response curves. Panel A shows the time courses of eht in the hippocampus of 17 male mice after two
seconds of stimulation at t ¼ 5 seconds (Hashemi lab). The thick red and black curves are the time courses of the
mean and standard deviation, respectively. The response curve are diverse and have different heights, peaks and
shapes. Panel B shows 17 randomly selected response curves in a systems population model of 1000 individuals.
The red and black curves are the time courses of the mean and the standard deviation of the 1000 model
individuals, respectively. In both the experiments and the model, most (but not all) curves descend below
baseline after peaking and then curve up towards the baseline. The mean curves and standard deviation curves
are similar in the experiments and in the system population model.
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the curves have returned to near baseline), the three parameters that contributed
most to the variation in response were the Vmax of TPH, the speed of the
autoreceptors, and the Vmax of MAT.
The populationmodel allows us to approach a quite difficult mathematical question
that would be very useful for understanding the biology and possible treatments.
Suppose one has two populations of mice, for example male and female or obese and
not obese or depressed and not depressed. Each of the two populations will produce a
large family of experimental responses and those families of curves may be quite
different. How can one estimate which parameters in the model cause the difference in
the families? This is a way of using the response eht curves to probe the differences
inside the neurons.
The expression levels of most enzymes can vary by about 25% or more between
individuals [1–3]. This means that the Vmax values of all the enzymes and trans-
porters in our model vary by at least 25% and that any population of individuals will
express this diversity. This poses large issues for drug discovery and treatment
because it means that different individuals will react very differently to drugs, as is
well-known [40–42]. Here, we present a simple example that shows how to use
variation in a small number of variables to investigate questions about drug effi-
cacy. In Figure 10 we show results from our systems population model where we
varied only two constants, the expression level (Vmax) of SERT and the expression
level of MAO, from 25–175% of normal. Each dot is an individual in a population of
500. The y-axis is the concentration of eht, extracellular serotonin, and the x-axis is
the expression level of SERT. The blue dots are the individuals with low MAO
activity and the red dots are individuals with high MAO activity. The conclusion is
clear. Blocking SERTs with an SSRI (equivalent to lowering the expression level)
will have a much greater effect on individuals with high MAO activity than on
individuals with low MAO activity. Therefore, the systems population model sug-
gests that it is high MAO individuals that will benefit the most from an SSRI. This
shows how population models can be used to target specific questions.
6. Real-time in vivo neurotransmitter measurement techniques
To better answer physiological questions of the brain, especially about mental
illness, it is critical to measure brain chemistry, specifically neurotransmitters.
Figure 10.
Variation of SERT and MAO activity. In the population model, we varied only SERT activity and MAO
activity. Each dot is one virtual individual, and the coordinates of each point are the activity of SERT
(normal = 1) and the steady state concentration of eHT. The blue dots are individuals that have very low MAO
activity and the red dots have very high MAO activity. Blocking the SERTs (changing the activity) has a much
greater effect on high MAO activity individuals than on low MAO activity individuals.
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Measuring neurochemistry is very challenging because neurotransmission is
dynamic, and the brain tissue is very delicate. The earliest brain analysis methods
utilized brain biopsies that were homogenized, separated and analyzed via HPLC
[43]. These methods are offline and give an overview of whole tissue content, but
not dynamic transmission. Microdialysis revolutionized brain analysis by utilizing a
probe implanted into the brain, perfused with artificial cerebrospinal fluid [44, 45].
At the distal end of the probe is a semi-permeable membrane with a cut-off point
such that analytes of interest can diffuse into the probe down a concentration
gradient. The outcoming fluid, the dialysate, is collected and analyzed with a sec-
ondary method such as HPLC. The time resolution of this method is typically tens of
minutes. Niche, electrochemical methods, such as fast scan cyclic voltammetry
(FSCV) and fast scan-controlled adsorption voltammetry (FSCAV) can measure the
subsecond temporal profile neurotransmission [33, 46, 47], outlined below.
6.1 Fast-scan cyclic voltammetry
Fast-Scan cyclic voltammetry is uniquely suited to measure neurotransmission
in vivo. Its fast temporal dynamics allows for neurochemical detection on a
subsecond timescale, approximately a thousand times faster than traditional cyclic
voltammetry. Furthermore, FSCV measurements are performed at microelectrodes,
typically carbon fiber microelectrodes (CFMEs). CFMEs have a small probe size
(diameter 7 μm) and are biocompatible, creating minimal tissue damage and negli-
gible immune response [48, 49]. Carbon electrodes also drive high sensitivity
because their highly negative surface preconcentrates positively charged transmit-
ters such as dopamine, serotonin, norepinephrine and histamine. These transmitters
are then readily oxidized at the carbon surface, making it an ideal material for
neurochemical measurements. Traditionally, FSCV has been utilized to measure
dopamine [50–52]. However recent advances have allowed for the detection of
other neurotransmitters, such as serotonin and histamine [24, 36, 53, 54].
Serotonin is measured using a CFME that has been modified by electropoly-
merization of a thin, uniform layer of Nafion. Nafion, a cation exchange polymer,
increases the electrode sensitivity to serotonin while reducing the electrode poison-
ing effects of serotonin metabolites [54]. For in vivo experiments, this electrode is
placed in the brain region of interest, such as the hippocampus, prefrontal cortex, or
SNr. Because FSCV is a background subtracted technique, serotonin is evoked using
an electrical stimulation placed in the MFB. Detection occurs by application of a
waveform optimized for serotonin measurements. [12] This waveform has a resting
potential of 0.2 V, scans up to 1.0 V, down to 0.1 V, and then back to the resting
potential of 0.2 V at a scan rate of 1000 Vs1, applied at a frequency of 10 Hz. The
signal is presented in the form of cyclic voltammograms (CVs) that qualify and
quantify the substrate. Figure 11 illustrates the FSCV experiment.
Histamine is particularly difficult to detect in vivo using FSCV because it lacks a
clear, sharp oxidation peak. The Hashemi Lab developed a waveform that produces
a unique electrochemical histamine signal. It has a resting potential of 0.5 V, scans
to 0.7 V, up to 1.1 V, and then returns to the resting potential of 0.5 V at a scan
rate of 600 Vs1. This waveform simultaneously detects serotonin and histamine
release in vivo [24, 36].
6.2 Fast-scan controlled adsorption voltammetry
One limitation of FSCV is that because of the large capacitive current generated
by the fast scan rate, it is a background subtracted technique [55]. This means that a
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change must be evoked, often electrically or pharmacologically. To address this
issue, Atcherly et al. developed the method of fast-scan controlled adsorption
voltammetry (FSCAV) to measure ambient concentrations of dopamine [56, 57].
This technique, illustrated in Figure 11B, was later adapted to measure serotonin
[33]. FSCAV occurs at the same microelectrodes as FSCV. Serotonin FSCAV is
performed in three steps: 1) The minimized adsorption step is implemented by
applying the waveform at 100 Hz for 2 seconds. 2) The potential is held at +0.2 V
for 10 sec for a period of controlled adsorption. 3) The waveform is reapplied at
100 Hz for 18 seconds. The CVs taken in the 3rd step are subtracted from the 1st
step and thus serve as the ambient measurement.
7. The chemical basis of neuroinflammation
The vast majority of mental illnesses are associated with inflammation, espe-
cially depression which is highly comorbid with inflammation [58]. Increased levels
of proinflammatory cytokines in the interleukin-1 and tumor necrosis factor fami-
lies are linked to neuroinflammation [59, 60] across many different brain disorders.
Chronic neuroinflammatory states have been implicated in neurodegenerative
Figure 11.
Illustrative representation of an FSCV vs. FSCAV experiment described in-text. A. Shows the stimulation of the
MFB to induce the release of serotonin in the CA2 and application of the serotonin waveform [53] to detect the
evoked change in serotonin concentrations in the extracellular space over time. B. Depicts the modified
waveform application for serotonin FSCAV [33] that negates the need for electrical stimulation to detect
ambient concentrations of serotonin in the extracellular space each minute. This figure was created with
Biorender.com.
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disorders such as Parkinson’s Disease [61, 62], Alzheimer’s Disease [63–65], and
multiple sclerosis [66, 67], in addition to depression [58, 68] and bipolar disorder
[69]. While these associations are clear, what is not known is the mechanism by
which inflammation affects neurotransmission. We began to address this question
by focusing on serotonin with FSCV and FSCAV. Serotonin is implicated in depres-
sion because the vast majority of antidepressants target the serotonin system [70].
Serotonin was first measured in vivo using FSCV in 1995 by Jackson et al. [53]. The
authors detected serotonin in the rat striatum by forcing dopaminergic terminals to
release serotonin following loading with 5-Hydroxytryptophan and dopamine
depletion with α-methyl-p-tyrosine. More recently, using the same waveform we
measured endogenous electrically evoked serotonin in the rat SNr [54]. Studies
have since expanded to characterizing serotonin in different brain regions, studying
differences in male and female mice, looking at serotonin and histamine co-
modulation and observing the effects of inflammation on this co-modulation. We
discuss our key findings below.
7.1 Serotonin dynamics in different brain regions
We first characterized evoked serotonin release and reuptake in the rat SNr
following electrical MFB stimulation [54]. The SNr is of interest for serotonin
detection as this area has the most dense serotonergic innervation in the brain and
thus serotonin is the primary neurotransmitter released following electrical stimu-
lation [71]. The signals obtained in vivo were pharmacologically verified using acute
administration of the DAT inhibitor, GBR 12909, and the SSRI citalopram. The
signals did not respond to DAT inhibition; however, following SERT inhibition, an
increase in max amplitude and a slowing of the reuptake was observed. Serotonin
response to varying doses of acute SSRI (1 mg kg1, 10 mg kg1, and 100 mg kg1)
was examined [72], with uptake t1=2 values increasing with dose concentration.
However, no dose dependent trend was observed for max amplitude values. Further
investigations of serotonin reuptake mechanisms [11] were performed by mathe-
matical modeling through the development of a Michaelis–Menten kinetic model as
previously described in Section 3. The presented model establishes a two uptake
mechanism for serotonin, a notion that was described back in the 70s as Uptake 1
and 2 [16]. Uptake 1 refers to the high affinity, low efficiency system characterized
by the serotonin transporters (SERTs) and Uptake 2 is serotonin clearance by the
low affinity, high efficiency mechanism afforded by the dopamine, norepinephrine,
organic cation, and plasma membrane transporters [16, 73].
While FSCV continues to provide insight into fast serotonin release and reup-
take dynamics, it is limited by its inability to measure steady-state or ambient
concentrations. To address this limitation, FSCAV was developed to detect absolute
concentrations of both dopamine [57] and serotonin [33] in vivo. This technique
(described above) yields fast, selective, and sensitive absolute concentrations of
serotonin. Using FSCAV we reported serotonin concentrations of 64.9  2.3 nM in
the CA2 [33]. Figure 12 shows ambient serotonin response to the monoamine
oxidase B inhibitor, pargyline, in comparison to the DAT inhibitor, GBR 12909.
Ambient serotonin levels increase following pargyline administration, but not fol-
lowing GBR administration, confirming that the signal is serotonin.
We expanded FSCV measurements of serotonin to the medial prefrontal cortex
(mPFC) [32], another region associated with depression. Here, we found an inter-
esting phenomenon whereby a double peak response was elicited in layers 1–3 of the
mPFC. Figure 13 shows examples of a single peak response as well as a variety of
double peak responses in this brain region. Interestingly, each discrete peak had its
own specific reuptake profile, thus we hypothesized that distinct axonal bundles in
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the MFB terminate in layer-dependent mPFC domains with specific uptake trans-
porters. A mathematical model confirmed that the double peaks could be explained
by diffusion of neurotransmitter to the electrode from two different sources, one
close and one further away.
Finally, in this part of our work, we compared the in vivo serotonin signals
between the SNr, the CA2 region of the hippocampus, and the mPFC [35]. We
found that the different responses could be modeled as a function of the percentage
of Uptake 1/Uptake 2 transporters with the model predicting the largest concentra-
tion of serotonin transporters in the SNr. We verified this notion with confocal
microscopy and concluded that FSCV could be a potentially useful tool for chemical
imaging of local cytoarchitecture. Interestingly, and counterintuitively, the SNr,
with the highest density of serotonin terminals and axons, had the lowest ambient
levels of serotonin. We realized that this was because of the high affinity of SERTs
(Uptake 1 transporters) in this region that serve to maintain steady state levels
lower than the other two regions with fewer SERTs.
7.2 Serotonin dynamics between the sexes
The prevalence of depression differs between males and females, with women
being more likely to suffer from the disorder than men [74–76]. As such, it is
important to investigate neurochemical and pharmacodynamic disparities across
the sexes. In the hippocampus, we observed no significant differences in the evoked
serotonin maximum amplitude or the t1=2 of clearance between male and female
mice [34]. Furthermore, no differences were detected between the mean signal and
Figure 12.
The dark blue markers represent the average response before and after pargyline (75 mg/kg, intra-peritoneal
(i.p.)) administration and the dark red markers represent the average response before and after administration
of GBR 12909 (15 mg/kg, i.p.). drug injection time is denoted by the yellow bar at 0 min. Representative
colorplots, CVs, and concentration vs. time curves are inset (top, pargyline; bottom, GBR 12909, α = predrug
and β = postdrug). (asterisks above blue markers indicate post hoc test: *p <0.0001.) reprinted with permission
from the American Chemical Society.
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the signal in different stages of the female mouse estrous cycle. This suggests that
there are no major sex differences in the release or reuptake machinery in drug
naive mice. Likewise, no significant differences were detected across sexes in
ambient levels of serotonin using FSCAV. Differences in clinical efficacy have been
observed following the administration of SSRIs, a class of commonly prescribed
antidepressants [77]. Following acute administration of the SSRI, escitalopram,
ambient serotonin concentrations increased significantly, however no differences
were seen between male and female mice. On the other hand, differences were
observed in the evoked serotonin reuptake decay curve. At all four doses given (1, 3,
10 and 30 mg/kg) the female mice had a lower percent change in reuptake com-
pared to the males. We speculated that in female mice, compensatory mechanisms
(likely via autoreceptors) exist to counteract hormone-mediated chemical fluxes
that may affect serotonin.
Figure 13.
Representation of single and double peaks reported by west et al. 2019 in the mPFC. The average serotonin
response is depicted in (A). Varying signals are shown in (B) with a traditional single peak displayed in (i.)
and five of the most common types of double peaks shown in (ii.-vi.). The inset contains the CVs of both peaks.
The first peak is shown in blue and the second in red. Reprinted with permission from Elsevier.
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7.3 Histaminergic transmission and modulation of serotonin
As outlined above, inflammation (peripheral and brain) is becoming synony-
mous with the pathophysiology of depression [58]. The monoamine histamine is a
major inflammatory mediator in the body [77], associated with allergic reactions.
However, less is known about histamine’s role in the brain. While traditionally
believed to be a neuromodulator in the CNS, recent studies have implicated hista-
mine in neuroinflammatory processes as well [78, 79]. To study fast histaminergic
dynamics, we optimized an FSCV waveform to simultaneously detect histamine
and serotonin in vivo [24, 36]. Histamine oxidation was pharmacologically validated
in the posterior hypothalamus following application of tacrine, a histamine N-
methyltransferase inhibitor, and thioperamide, an H3 receptor antagonist. Acute
tacrine administration slowed the reuptake of histamine significantly, while
thioperamide slowed the reuptake and increased the max amplitude. Upon electro-
chemical release of histamine, a rapid inhibition of serotonin is observed as shown
in Figure 3. In this figure, release and reuptake of histamine (a) and serotonin (b)
are shown before and after thioperamide (H3 receptor antagonist) administration,
where the dots are the result of a simple mathematical model where the receptor
and autoreceptor strengths were changed dynamically by hand. Using the new full
histamine and serotonin models (Sections 4 and 5) with the chemistry of the
autoreceptors and the H3 receptors, we were able to predict the experimental results
just by using the release and reuptake curve for histamine in the extracellular space
that we previously measured.
7.4 Serotonin and histamine in inflammation models
The inhibition of serotonin by histamine fueled our interest in the co-
modulation of these analytes in inflammation models. In recent work, we found
that upon acute lipopolysaccaride (LPS) induced inflammation, ambient serotonin
levels rapidly decreased as a function of increased histamine. Escitalopram was
much less capable of increasing the serotonin levels under this inflammation state.
We found that this was because escitalopram (and other common antidepressants)
inhibit histamine reuptake. This inhibition raises histamine, which depresses sero-
tonin release, counteracting the effect of the antidepressant on the SERTs. Only
with the dual strategy of inhibiting serotonin reuptake (by an SSRI) and inhibiting
histamine synthesis were we able to return the serotonin to pre-inflammation
control levels. We are now actively studying serotonin/histamine co-modulation in
other inflammation/depression models in mice including chronic stress and
neurodegeneration.
8. Future outlook
Our in vivo studies have allowed us to measure and compare and contrast
serotonin in different brain regions, to study serotonin dynamics in male and
female mice, to investigate serotonin and histamine co-modulation and to ask how
this modulation changes under inflammation. This program has provided invalu-
able information about the dynamics of these two modulators in health and patho-
physiology in mice. Our future goals are to apply our findings to ex vivomodels that
more closely mimic human inflammation as a path towards depression diagnosis
and treatment. We are exploring a variety of stem cell models, derived from
humans, as model systems for personalized diagnostic and drug screening plat-
forms. The continuing, active collaboration and innovation between the
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experimentalists and the mathematical modelers, as has been the case in the last
seven years, will drive novel discoveries in our future program.
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DRN Dorsal raphe nucleus
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